Previous Close | 31.70 |
Open | 30.91 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's Range | 30.33 - 31.41 |
52 Week Range | 17.20 - 32.31 |
Volume | 415,020 |
Avg. Volume | 604,432 |
Market Cap | 1.638B |
Beta (5Y Monthly) | 1.20 |
PE Ratio (TTM) | 13.11 |
EPS (TTM) | 2.36 |
Earnings Date | May 03, 2021 - May 07, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 34.50 |
U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.
On Friday afternoon, Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the U.S. Food and Drug Administration (FDA) had approved Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients between the ages of 6 to 17. As a result of this regulatory update, shares of the biopharmaceutical company are rising sharply on Monday and were up by 10.2% as of 1:49 p.m. EDT after jumping by as much as 11.4% earlier in the day. It hasn't been an easy road for Supernus Pharmaceuticals' attempt to earn approval for Qelbree: The company conducted four phase 3 clinical trials with over 1,000 ADHD patients to demonstrate the safety and efficacy of this medicine.
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.